Piramal Pharma Final Dividend Record Date on July 16: What It Means for Shareholders?

Piramal Pharma has set July 16, 2025, as the record date for its final dividend. On May 14, 2025, Piramal Pharma board declared a final dividend of ₹0.14 per share. 

Piramal Pharma said in an exchange filing, “The Board of Directors has recommended a final dividend of Rs. 0.14/- per Equity Share of Rs. 10/- each for the financial year ended 31st March 2025, which will be paid / dispatched after the 5th Annual General Meeting, subject to the approval of shareholders of the Company.” 

What Does Piramal Pharma Dividend Record Date Mean for Shareholders?

As Piramal Pharma has set July 16 as the record date for its final dividend, meaning that July 15 marks the last day to buy Piramal Pharma shares to become eligible for the final dividend. Further, any shares bought on or after July 16 (record date), won't be eligible for the final dividend due to the T+1 settlement rule.

Also Read: Upcoming Dividends in July 2025: Nestle India, Biocon, BHEL, TCS, Bharti Airtel & More

Piramal Pharma Management Take on Q4FY25 Earnings

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY25 has been a steady year for the company as we crossed $1 Bn in revenues with 12% YoY growth accompanied by 17% EBITDA margin and 5x increase in Net Profits, in-line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x, while making regular investments in capabilities and capacities for future growth.

During the year, we progressed well on our key performance metrics such as growth in innovation related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business. We believe we are on track to deliver on our FY2030 aspirations of becoming a $2bn revenue company with 25% EBITDA margins and high teens ROCE.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.